Biotech & Research

Toronto -- Syneos Health experts will lead a free webinar on December 1, 2026, at 11am EST (5pm CET) on how neuroscience sponsors are changing patient identification, endpoint selection and treatment-response assessment across CNS disorders. Xtalks is hosting the session, titled "Neuroscience Development: Are We Measuring What Matters?"

Disease heterogeneity and response variability are pressuring traditional trial design

Alzheimer's disease, Parkinson's disease and psychiatry trials face disease heterogeneity, limited trial accessibility and variable treatment response. These factors are forcing sponsors to reassess how they identify patients, measure treatment effects and make development decisions. Panelists will examine why traditional measures of treatment response are being re-examined and how sponsors are evaluating endpoints that better capture clinically meaningful change.

Warsaw – November 09, 2026 -- Ingenix's "Thalamus Reasoning" model ranks first among 29 models on LongevityBench, the independent benchmark for language models in cellular aging research, with a mean rank of 1.42 across the benchmark's 14 ranked tasks. The next best model scores 4.42. The best frontier model, Claude Opus 4.6, scores 9.85.

Ingenix's 9-billion-parameter model wins 11 of 14 benchmark tasks

The model was built by a small team and outperforms 28 published models, including systems from leading frontier labs. It also beats the best non-LLM baseline on eight tasks.

On DNA methylation age prediction, Thalamus Reasoning posts an error of 3.36 years. The best text-prompted model on the same Qwen3.5-9B base scores 12.9 years, and the Horvath clock scores 4.67 years. On transcriptomics ordering, the model reaches 0.828 accuracy against 0.671 for the best other LLM.

New York – November 06, 2026 -- Inductive took first place in the OpenADMET CYP Direct Inhibition Blind Challenge, ranking ahead of more than 270 eligible participants. It is the company's fourth consecutive first-place finish in an OpenADMET competition.

NVIDIA finishes third and Recursion fourth in the CYP field

Participants predicted inhibition potency (pIC50) against four CYP isoforms (CYP3A4, CYP2D6, CYP2C9 and CYP1A2) for 750 compounds. The measurements for those compounds were withheld until the challenge closed. The field included teams from leading biopharma, academic and AI organizations.

CYP enzymes metabolize the majority of small molecule drugs. Compounds that inhibit them can cause dangerous drug-drug interactions, so drug hunters need to flag this liability early and steer designs away from it.

WUXI – November 05, 2026 -- NORROY BIOSCIENCE presented its radiopharmaceutical pipelines in eight Top Rated Oral Presentations and three e-posters at the 39th Annual Congress of the European Association of Nuclear Medicine (EANM'26), held October 17-21 in Vienna, Austria. The China-based, late-stage clinical biotech also reached preliminary cooperation intentions with Esente Healthcare and other international partners on radiopharmaceutical automation equipment.

SAN MATEO – November 05, 2026 -- Astrosalva Therapeutics, a privately held preclinical biotech developing treatments for Alexander disease and the cerebral form of adrenoleukodystrophy (cALD), has appointed Wendy Erler, Senior Vice President of Patient Affairs at Sarepta Therapeutics, as the first member of its Strategic Advisory Board.

Erler to steer patient engagement and trial planning at Astrosalva

Erler will advise on patient and community engagement strategy. Her remit includes working with existing community natural history registries and bringing patient and caregiver perspectives into future clinical trial planning.

Co-founder and CEO Paul Schmidt said the order of announcements is deliberate: Erler is the first advisor named, because the company wants families to know it is being built around patients and their communities.

COLOGNE, GERMANY – November 1, 2026 – Informa Connect will host BIO-Europe 2026 in Cologne, Germany, on November 9–11, 2026, convening more than 6,000 senior executives from the global biotech, pharmaceutical, and investment sectors. The 32nd edition of the conference arrives as senior leaders report renewed confidence in biopharma dealmaking, even though financing challenges continue. Programming focuses on how scientific innovation is financed, developed, and brought to patients, alongside structured one-to-one partnering. For company teams, investors, and pharmaceutical partners, the event combines deal-making, strategic debate, and regional ecosystem access in one setting.

Denver – September 17, 2026 -- The International Association for the Study of Lung Cancer (IASLC) has launched a Complimentary IASLC Full Membership program for healthcare professionals in World Bank-designated low-income and lower-middle-income economies, eliminating financial barriers to its global thoracic oncology network.

Board approves fee waiver to widen access to research and clinical resources

The IASLC Board of Directors approved the initiative this spring, extending full membership benefits at no cost to clinicians, researchers, nurses, allied health professionals and patient advocates in eligible countries. Eligibility is determined annually using World Bank country income classifications.

United States – September 15, 2026 -- Hyundai Motor America has committed more than $300 million to pediatric cancer research since 1998 through its Hope on Wheels program, a figure the automaker is now amplifying with a new national campaign, The Mark of a Warrior, timed to National Childhood Cancer Awareness Month in September.

Hyundai ties campaign launch to a diagnosis every 36 minutes

One child is diagnosed with cancer every 36 minutes in the United States, according to Hyundai, underscoring the urgency behind a 28-year fundraising effort that has supported research benefiting more than 40,000 children. The company, its dealer network and buyers of every new Hyundai fund the program.

Washington – September 15, 2026 -- Donation after circulatory death (DCD) heart transplantation expanded rapidly across the United States between 2019 and 2024 without any measurable decline in early clinical outcomes, according to research published in the September 2026 issue of the Journal of Cardiac Failure (JCF).

Registry data on 1,489 patients show no rise in graft failure or mortality

Investigators analyzed U.S. registry data covering 1,489 adult DCD heart transplant recipients, comparing the early adoption period of 2019-2021 with the national expansion period of 2022-2024. The analysis found no significant differences in one-year graft failure, mortality, need for renal replacement therapy, re-transplantation or hospital length of stay between the two periods. Outcomes remained consistent even among higher-risk recipients, as DCD transplantation spread to a growing number of transplant centers nationwide.

Barnard, Vt. – September 14, 2026 -- MIB Agents began accepting letters of intent on September 9 for its 2027 OutSmarting Osteosarcoma research grant cycle, offering a combined $150,000 to fund translational studies on the pediatric bone cancer.

Two grants totaling $150,000 target established and emerging researchers

The 2027 cycle includes a $100,000 Hero Grant and a $50,000 Hope Young Investigator Grant. Since launching in 2017, the program has distributed more than $2.9 million across 37 investigators studying osteosarcoma, an aggressive primary bone cancer diagnosed in roughly 1,000 people annually in the United States, nearly half of them children, adolescents and young adults.